One of the things that investors need to keep in mind with penny stocks is that these are volatile in nature. The wrong investment can lead to steep losses. So, it’s now a well-established fact that investors need to do their research diligently in order to find the best penny stocks to buy. Just as quickly as they can fall with the wrong pick, penny stocks can explode higher if you choose wisely.
Being that this is the last day before the holidays begin, we may see interesting trading action. Liquidity sometimes becomes much lighter and when it comes to penny stocks, low liquidity paired with smaller share structures can present unique opportunities.
[Read More] Top Penny Stocks To Trade This Week? 1 Up 174% This Month
Just keep in mind that if you do find low float penny stocks that there’s enough liquidity to exit a position as easy as it is to enter that position. Keeping this in mind, here is a look at three penny stocks to watch on Friday.
Penny Stocks To Watch #1 Inovio Pharmaceuticals
The first penny stock to consider is that of Inovio Pharmaceuticals Inc (INO Stock Report). Shares climbed by as much as 30.80% on Thursday after Roth Capital set a target price of $13. That reflects a potential fivefold return from its Wednesday’s close and naturally, it fired up INO stock.
One of the company’s leading treatments, VGX-3100 is another reason behind the optimism. It is a vaccine that meant for stimulating a patient’s immune system in order to tackle pre-cancerous lesions caused by human papillomavirus. The company is working on three different types of lesions. Furthermore, interim data from the Phase 2 trials in two of those lesion variants are expected to be published in Q1 2020.
Last month, Inovio announced more updates to its experimental drugs INO-5401 plus INO-9012. These were combined with Regeneron (REGN)’s Libtayo. Interim data demonstrated positive results in brain cancer patients, sparking further optimism around the company’s treatment pipeline.
Penny Stocks To Watch #2 Selecta Biosciences
The second penny stock that may deserve attention is Selecta Biosciences Inc (SELB Stock Report). It’s been a penny stock that we’ve followed since early November and had an impressive rally on Thursday. The company announced that it entered into a licensing agreement with Asklepios BioPharmaceutical. According to the agreement, Asklepios is going to develop and commercialize Selecta’s immune tolerance platform, ImmTOR.
The platform is going to be used by Askpelios to create is an adeno-associated virus gene therapy for Pompe disease. Keep in mind that the two companies had previously announced a strategic partnership this summer. The companies would manufacture, develop, and commercialize specific treatments for adeno-associated viruses. The terms of this partnership making Selecta eligible to receive upfront and milestone payments of over $240 million. The company also gains royalties on product sales.
Read More
- Do Penny Stocks Ever Pay Off? The Answer May Surprise You
- These Penny Stocks Just Hit New Highs For December 2019
- 3 Penny Stocks To Watch Hitting Fresh December Highs
It goes without saying that it is a significant development for Selecta. As a result, SELB stock rallied by as much as 45% after the news broke. Shares extended gains during premarket trading on Friday, hitting highs of $2.24.
Penny Stocks To Watch #3 ENDRA Life Sciences
Last but not least, the ENDRA Life Sciences Inc (NDRA Stock Report) rallied impressively on Thursday. It came after the company made a significant announcement with regard to one of its products. The company is best known for its Thermo Acoustic Enhanced UltraSound and on Thursday it announced that it has managed to submit its Technical File meant for CE Mark.
“It is the culmination of years of scientific research, quality system implementation and clinical data collection, and I’m very proud of the ENDRA team. Our technical file is now in review and we anticipate receiving CE Mark for the TAEUS FLIP device in the first half of 2020, with the subsequent commercialization of the TAEUS liver system expected to commence in Europe in mid-2020. ENDRA also expects to submit a 510(k) application to the U.S. Food and Drug Administration (FDA) for 510(k) clearance in 2020.”
Francois Michelon, ENDRA’s chairman and chief executive officer
It was a significant development and no surprise NDRA stock rallied by as much as 36% on the back of the news.
